Re: oxgn snss
Black_jack wrote:
Quoteheut an board gesprungen 19000stk oxgn und 14000snss mal schauen ich hoffe klappt besser als bei rpc :lol:
Nette Positionen 
Viel Glück!
-
-
Re: oxgn snss
Black_jack wrote:
Quoteheut an board gesprungen 19000stk oxgn und 14000snss mal schauen ich hoffe klappt besser als bei rpc :lol:vorsicht, wenn du noch mehr oxgn kaufst, musst du dich bei der SEC melden, erste meldepflicht ist bei 3% :lol:
-
Hot Pharma Stocks / Ideen / Blockbuster
Ich bin auch nochmals aufgesprungen. Ich hoffe das Ding hält! Sonst sind halt meine Gewinne von gestern gegrillt. Die Marktkapitalisierung ist für mich eigentlich auch zu klein. Wenn man sich aber überlegt, dass bei einer Zulassung des Medikaments die Marktkapitalisierung mehr als verzehnfacht, dann ist das schon eine Investition wert. Die Ergebniss gefallen mir persönlich. Jedenfalls ist halt das grosse "Contra" die Gelder, die nicht da sind, um die Trials zu beenden. Die teuerste Phase ist nun mal die letzte und ich bin überzeugt, bevor die Firma aus Geldnot einbricht, kommen Investoren/Pharmakonzerne hinzu. Also eben, ich bin mal wieder dabei. Ist schwer zu sagen, was morgen kommt. Kann sein, dass es bis auf die 0.27 runtergeht. Da ich aber langfristig (oder bis zum nächsten Run) investiert bin, interessiert mich das nicht
-
Hot Pharma Stocks / Ideen / Blockbuster
Viel Erfolg alchimist und equity holder.
-
Hot Pharma Stocks / Ideen / Blockbuster
PS: Ich möchte hier keine Kaufempfehlung oder ähnliches aussprechen. Die Aktie ist mehr als riskant. Schon ich alleine kann den Kurs beeinflussen.
-
Hot Pharma Stocks / Ideen / Blockbuster
equity holder wrote:
QuotePS: Ich möchte hier keine Kaufempfehlung oder ähnliches aussprechen. Die Aktie ist mehr als riskant. Schon ich alleine kann den Kurs beeinflussen.deshalb wären wir froh wenn du uns deine käufe vorankündigen würdest
-
Hot Pharma Stocks / Ideen / Blockbuster
Achtet in den nächsten Tagen mal auf OPXA. Könnte evtl. anfangen raufzuziehen.
PS: Auch hier bitte zuerst ins Forum schreiben bevor Ihr kauft/verkauft
-
Hot Pharma Stocks / Ideen / Blockbuster
Hehe, OPXA beobachte ich schon den ganzen Tag. Sehr interessanter Titel. Aber ich denke, dass er erst nochmals etwas zurückgeht, da er nun 2 Tage angezogen hat.
-
Hot Pharma Stocks / Ideen / Blockbuster
Wenn er zurückgeht, ist es vorbei. (für longs)
-
Hot Pharma Stocks / Ideen / Blockbuster
Bin ja spekulativ bei ARYx Therapeutics drin:
http://www.google.com/finance?q=NASDAQ:ARYXDas ist auch eine tickende Zeitbombe die jederzeit hochgehen könnte.
-
Hot Pharma Stocks / Ideen / Blockbuster
hier noch ne was. kenne die Aktie gar nicht und habe mich nicht damit beschäftigt aber die Firma erwartet heute eine FDA Zulassung:
SVNT
[Blocked Image: http://a.imagehost.org/0734/svnt.jpg]
gruss n good night
-
Denreon (DNDN)
Dendreon hat einen starken Support bei 40 USD. Da wo ich letzes mal gegen die Wand gelaufen bin.
-
Hot Pharma Stocks / Ideen / Blockbuster
SAVIENT PHARMCTLS : FDA Approves KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy
http://www.4-traders.com/SAVIE…Gout-in-Adult-P-13456570/
http://www.bloomberg.com/news/…-way-for-acquisition.html
Hat sich gelohnt noch 330 Shares zu halten.
-
Hot Pharma Stocks / Ideen / Blockbuster
Savient Pharmaceuticals, Inc. (Public, NASDAQ:SVNT)
After Hours: 17.75 +2.99 (20.26%)
-
HRBR
After Hours: 0.400 +0.165 (70.21%)
Harbor BioSciences Apoptone(R) for Prostate Cancer Shows a Partial Overall Response
New Positive Phase I/IIa Data -
ARNA 3.91$
wenn sie heute nicht über oder auf 4$ schliesst dann ist ARNA unter der 200 tageslinie was Platz öffnet zu 3-3.50$. Firmen rund um downgraden ARNA ausser eine die belässt ihr overweight rating mit Preisziel 10$.
Piper Jaffray Says Arena Pharmaceuticals (ARNA) Sell-Off is an "Overreaction"
Quote:
QuotePiper Jaffray just issued some comments on Arena Pharmaceuticals (Nasdaq: ARNA), which is finding its shares under extreme pressure today after the FDA posted briefing documents which highlighted safety concerns.Display MoreThe firm said the safety concerns were expected and while the documents do place a higher emphasis on a broader set of concerns than anticipated, they believe the sell-off is an overreaction.
The firm highlighted the three areas of FDA safety concerns:
* Valvulopathy. The documents cite a 1.07 relative risk of valvulopathy and state this rules out a 55% increase in risk. This analysis implies the FDA is using a stricter 2-sided test which is important since the agreed cut off is ruling out a 50% increase in risk and the more stringent test places the results just beyond that cut off. We still believe the valvulopathy data taken together with mechanistic data are convincing on the question of valvulopathy.* Cognitive and Neuropsychiatric Concerns. The documents cite an imbalance in "perceptual or dissociative related events" of 21% incidence on lorcaserin vs. 12% on placebo. However, the documents also concede a wide range of event terms contribute to this. These terms include relatively benign AEs such as dizziness and fatigue. More concerning in our opinion is a cited 3X excess in cognitive events, although the documents cite these as infrequent.
* Carcinogenicity. The documents discuss a higher incidence in malignant mammary tumors in rat studies that occur at doses within 7X of the proposed human dose for female rats and 17X for male rats treated for two years as well as increases in other tumor types. The question at hand is whether this represents an adequate safety margin and we are unsure of what standards the panel member might apply in judging this. Importantly, however, the documents acknowledge no imbalances incarcinogenicity events in the human clinical trials. In Phase III studies, some 2 year data was collected, exceeding FDA requirements.
The firm said. "the ultimate view to be taken by panel members is the relative efficacy of lorcaserin versus its side effect profile. While we are confident that lorcaserin met the specified efficacy requirements for approval, the margin was slim which may be concerning to some panel members."
The firm is reiterating their Overweight rating and $10 price target.
Shares of ARNA are down 39% to $4.16.
-
Savient (SVNT)
Was hier noch drinliegt in nächster Zukunft? Hat hier jemand investiert/getradet?
(Berifft Beiträge weiter oben).
US Markt > News > SAVIENT PHARMACEUTICALS ORD (SVNT) News Prognosen
15-09-2010 15:30 Savient shares rally as FDA approves gout drugSept 15 (Reuters) - Shares of Savient Pharmaceuticals Inc jumped 27 percent on Wednesday, a day after the company's gout drug Krystexxa got U.S. regulatory approval making it the first approved treatment for gout in adults who do not improve with conventional therapies.
The approval is also expected to trigger a renewed interest in the company that has been looking for a strategic deal, and some analysts expect a deal within three to four months.
'We assume that discussions have been ongoing, and that the label has been distributed together with term sheets: we would not be surprised to see a sale of the company by the end of the quarter,' Roth Capital Partners analyst Andrew Vaino said in a note.
Companies with a rheumatology exposure and sales force could see Savient as a meaningful fit and Abbott Laboratories Inc, Bristol-Myers Squibb, Roche Holding AG , Amgen Inc, Johnson & Johnson and Pfizer Inc were named as potential suitors.
On a conference call with analysts Wednesday, Savient said it was still looking to sell the company but did not disclose any other details.
Krystexxa, which was denied approval last year by the U.S. Food and Drug Administration citing manufacturing issues, was approved on Tuesday with a 'black-box' warning -- a strong label warning -- regarding allergic and infusion reactions.
East Brunswick, New Jersey-based Savient is also required to do a post-approval study in 500 patients to further evaluate the frequency and severity of infusion and allergic reactions.
The boxed warning did not come as a surprise given the adverse cardiovascular events that were seen during the trials, and analysts said the required risk evaluation and mitigation strategy was 'mild' and would not impact the drug's usage or adoption.
'We continue to believe Krystexxa could become a best-in-class therapy with its differentiated profile and represent a new treatment paradigm for this unmet need to warrant a $400 million peak potential by 2013,' Global Hunter Securities analyst Kimberly Lee said.
According to Thomson Reuters data, the drug is expected to reach sales of $173 million and capture a 23 percent market share by 2014.
About 5 million Americans suffer from gout, in which a build up of uric acid causes swollen joints. Of those, about 40,000 to 60,000 see no improvement with other therapies, according to the company.
'For the pricing of the drug, the Street expects up to $100,000 (per patient per year), whereas our survey shows about $25,000 to be cost-prohibitive for Krystexxa use,' Jefferies and Co analyst Eun Yang said.
Savient expects the drug to be available by prescription in the United States later this year and said it was well advanced in its preparations for the U.S. launch.
Krystexxa was also granted an orphan drug designation by the FDA in 2001 that can provide the drug seven years of market exclusivity.
In September last year, Savient had said it planned to cut 26 jobs, or about 38 percent of its workforce, to reduce costs and focus on the resubmission of marketing application for the drug.
Other U.S. companies developing gout treatments are Regeneron Pharmaceuticals Inc, Ardea Biosciences Inc and BioCryst Pharmaceuticals Inc. Swiss drugmaker Novartis AG is also developing a treatment for gout.
Savient shares, which have gained 22 percent over the past three months in anticipation of a FDA nod for the drug, were up 27 percent at $18.75 in premarket trade. They closed at $14.76 Tuesday on Nasdaq.
(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel) Keywords: SAVIENT/SHARES (esha.dey@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: esha.dey.thomsonreuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Gruss,
Simona -
Hot Pharma Stocks / Ideen / Blockbuster
Rein bei Opexa Therapeutics OPXA @1.63
-
Hot Pharma Stocks / Ideen / Blockbuster
Rein bei Ironwood Pharmaceuticals
http://www.google.com/finance?q=NASDAQ%3AIRWD -
Hot Pharma Stocks / Ideen / Blockbuster
@ Simona
SVNT hat die FDA Zulassung für ihr Medi http://www.krystexxa.com/ bekommen. (Mitetl gegen Gicht aber man muss 2 andere Medis vorher einnehmen damit es einen nicht hops nimmt):?.
ich habe diesen Event nicht getradet, da ich so gut wie nix über Savient weiss. scheint mir eine sehr spezielle firma zu sein, welche sich aber in den nächsten Wochen wahrscheinlich für den höhchstbietenden zum verkauf anbieten wird.
gruss